EpiPen

Janney: Cannabis, Naloxone, Adrenaline The Perfect Mix For Insys

Analyst: Insys To Benefit As FDA Pushes Naloxone Access

Teva Wins FDA Approval For Generic Epinephrine

Analyst: Insys To Benefit As FDA Pushes Naloxone Access

Teva Wins FDA Approval For Generic Epinephrine

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

A Peek At Adamas Ahead Of FDA Approval

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

|

A Peek At Adamas Ahead Of FDA Approval

|

It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date

|

What Makes Mylan's Newest EpiPen Lawsuit Different?

|

EpiPen Recent News

Imprimis Challenges Mallinckrodt's Acthar

|

How Did A Maligned Mylan Surprise To The Upside With 2017 Outlook?

|

Short Sellers Bet Against Generic EpiPen

|

Mylan's EpiPen Dropped From Cigna's Coverage List

|

How Does Mylan's $300 Choice Compare To Other Generic EpiPens?

|

Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen

|

Mylan's Q3 Report Tries, Fails To Shift Focus Away From EpiPen Controversy

|

The Things You Need To Know Ahead Of Mylan's Q3 Earnings

|

Mylan Surrenders Some Of Its Gains From EpiPen Settlement

|

Mylan Analysts Respond Positively Following EpiPen Classification Settlement

|

After-Hours: 2 Stocks On The Move On Another Slow Friday Afternoon

|

Epipen's Profits Are Actually A Lot Higher Than Mylan Originally Told Congress

|

USA Today On EpiPen Saga: Calling It 'Controversial' Is Far From Haphazard

|

Controversy Pullback Offers Good Entry Point For Mylan

|

Mylan's CEO Showed 'Very Little Empathy,' Bill George Says

|

Mylan Investors Should Be Asking Where (And Who) Robert Coury Is

|

Another Election Year View On Healthcare ETFs

|

MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says

|

Mylan Announces $300 Version Of EpiPen

|

Pharma Companies Are Spending Millions To Sustain High Drug Prices

|

Mylan Is Offering An EpiPen Savings Card, But A Lot Of People Will Still Get Screwed

|

Selling Pressure Continues For Mylan

|

Mylan 'Took The Sting' Out Of The EpiPen Controversy

|